---
title: 'NDA 리뷰: crizotini (Xalkori, Pfizer)'
date: 2017-10-13
categories: [review]
tag: [crizotinib]
---

<https://en.wikipedia.org/wiki/Crizotinib>

- Ix: ALK-positive NSCLC, metastatic NSCLC
- accelerated approval : 2011 Aug
- BID
- kinase inhibitor
- c-met, alk, ros (kinase임) 를 targeting 한다.
- selective kinase inhibitor
- ALK는 lymphoma에서 발견됨. 항상 active한 상태로 발견됨. kinase domain - translocation.
- trials of crizotinib against ELM4-ALK NSCLC - accelerated approval
- Enrichment Trials를 통해서 빠른 승인

